Use of bisphosphonates in cancer patients.
Body
J J
JJ
Bone Metabolism Unit, Institut Jules Bordet, Université Libre de Bruxelles, Belgium.
Coleman
R E
RE
Piccart
M
M
D019386:Alendronate / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000150:complications* / Q000517:prevention & control / Q000556:secondary*; D001862:Bone Resorption / Q000517:prevention & control; D001943:Breast Neoplasms / Q000150:complications*; D004002:Clodronic Acid / Q000627:therapeutic use; D004164:Diphosphonates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000627:therapeutic use; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D009101:Multiple Myeloma / Q000188:drug therapy; D010014:Osteolysis / Q000188:drug therapy / Q000209:etiology; D010146:Pain / Q000188:drug therapy; D000077268:Pamidronate; D013329:Structure-Activity Relationship
D004164:Diphosphonates; D004002:Clodronic Acid; D012968:Etidronic Acid; D000077268:Pamidronate; D019386:Alendronate